Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has emerged as the standard of care for evaluating locoregional and metastatic prostate cancer [9, 10]. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.